Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Graviti Pharmaceuticals has rapidly expanded its portfolio since commencing commercial operations in October 2018. The company has launched multiple generic drugs for the US market with a focus on complex generics that are challenging to formulate. It maintains healthy operating margins (18–25%) and robust revenue growth—FY24 revenue was ₹460 crore ($55 million USD). The company continues to invest heavily in R&D (~7–8% of revenue) to expand its product offerings further. Its manufacturing facility in Hyderabad, India, is FDA-approved and designed for high-volume production with strict quality standards.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Graviti Pharmaceuticals.